Clonazepam

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Rivotril; Belgium: Rivotril; Bulgaria: Rivotril; Cyprus: Aklonil, Clonotril, Rivotril; Czech Republic: Rivotril; Denmark: Rivotril; Estonia: Rivotril; Finland: Rivatril; France: Rivotril; Germany: Antelepsin, Rivotril; Greece: Rivotril; Hungary: Clonazepam, Rivotril; Ireland: Rivotril; Italy: Rivotril; Latvia: Clonazepam; Lithuania: Clonazepam, Rivotril; Luxembourg: Rivotril; Malta: Rivotril; Netherlands: Rivotril; Poland: Clonazepamum, Rivotril; Portugal: Rivotril; Romania: Rivotril; Slovakia: Rivotril; Slovenia: Rivotril; Spain: Rivotril; Sweden: Iktorivil, Rivotril; UK: Rivotril.

North America

Canada: Clonazepam; USA: Clonazepam, Klonopin.

Latin America

Argentina: Alerion, Ciclox, Clonagin, Clonasedan, Clonax, Clonazen 2, Clonazepam, Cloner, Diocam, Edictum, Felanor, Flozepam, Induzepam, Leptic, Neuryl, Paditex, Placidiax, Riuclonaz, Rivocler, Rivotril, Sedovanon, Sensaton, Solfidin, Tecepin; Brazil: Clonazepam, Clonotril, Epileptil, Navotrax, Rivotril; Mexico: Clonazepam, Clozer, Kenoket, Kriadex, Rivotril, Zymanta.

Asia

Japan: Landsen, Rivotril.

Drug combinations

Chemistry

Clonazepam: C~15~H~10~ClN~3~O~3~. Mw: 315.71. (1) 2H-1,4-Benzodiazepin-2-one, 5-(2-chlorophenyl)-1,3-dihydro-7-nitro-; (2) 5-(o-Chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. CAS-1622-61-3 (1969).

Pharmacologic Category

Anxiolytics, Sedatives, and Hypnotics; Benzodiazepines. Anticonvulsants; Benzodiazepines. (ATC-Code: N03AE01).

Mechanism of action

Exact mechanism of anticonvulsant, sedative, and antipanic effects is unknown; however, mechanism appears to be related to the drug’s ability to enhance the activity of γ-aminobutyric acid (GABA). Suppresses the spike-and-wave discharge in absence seizures by depressing nerve transmission in the motor cortex. Depresses all levels of the CNS, including the limbic and reticular formation, by binding to the benzodiazepine site on the GABA receptor complex and modulating GABA.

Therapeutic use

Petit mal variant (Lennox-Gastaut), akinetic, and myoclonic seizures. Petit mal (absence) seizures unresponsive to succimides. Panic disorder with or without agoraphobia.

Pregnancy and lactiation implications

Teratogenic in some animals. Clonazepam crosses the placenta. Benzodiazepine use during pregnancy is associated with increased risk of congenital malformations. Nonteratogenic effects (neonatal flaccidity, respiratory and feeding problems, and withdrawal symptoms) during the postnatal period also reported. Not recommended during lactation.

Unlabeled use

Restless legs syndrome. Neuralgia. Multifocal tic disorder. Parkinsonian dysarthria. Bipolar disorder. Adjunct therapy for schizophrenia.

Contraindications

Hypersensitivity to clonazepam or any component of the formulation (cross-sensitivity with other benzodiazepines may exist). Significant liver disease. Narrow-angle glaucoma. Pregnancy.

Warnings and precautions

Benzodiazepines have been associated with anterograde amnesia. May cause CNS depression. Use with caution in patients receiving other CNS depressants or psychoactive medication (may potentiate effects with other sedative drugs or ethanol; concurrent use with valproic acid may result in absence status). May cause paradoxical reactions, including hyperactive or aggressive behavior, mainly in adolescent/pediatric or psychiatric patients. Use with caution in history of drug abuse or acute alcoholism. Tolerance, psychological and physical dependence may occur with prolonged use. Does not have analgesic, antidepressant, or antipsychotic properties. Worsening of seizures may occur when added to patients with multiple seizure types. Use with caution in hepatic/renal impairment. Use with caution in impaired gag reflux/respiratory disease. Use with caution in debilitated patients. Use with caution in the elderly (benzodiazepines have been associated with falls and traumatic injury). Rebound or withdrawal symptoms may occur following abrupt discontinuation or large decreases in dose (caution when reducing dose or withdrawing therapy). Flumazenil may cause withdrawal in patients receiving long-term benzodiazepine therapy.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart